DBV Technologies Projects Cash Runway Through Q3 2027 Amid FDA BLA Filings for VIASKIN
DBV Technologies (NASDAQ: DBVT) has announced that its current cash reserves are expected to sustain operations through the third quarter of 2027. This financial runway supports the company's ongoing regulatory efforts, specifically the advancement of Biologics License Applications (BLAs) for its peanut allergy treatment, VIASKIN. A key milestone reported by CEO Daniel Tassé is the recent filing of a BLA for the pediatric population aged 4 to 7 years. The company is simultaneously managing manufacturing preparations and sequential FDA reviews to support the potential commercialization of the product.
Tickers: $DBVT
Topics: Biotechnology Clinical Development FDA Approval Process